Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.49 |
| ▸ | MMP3 | P08254 | 7/20 | 0.49 |
| ▸ | MMP1 | P03956 | 5/20 | 0.49 |
| ▸ | MMP9 | P14780 | 3/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | MMP7 | P09237 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617307 | 0.92 | MMP2 (0.50) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL4880753 | 0.92 | MMP2 (0.50) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL4887577 | 0.91 | MMP2 (0.51) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL4877176 | 0.91 | MMP2 (0.53) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL14066490 | 0.89 | MMP3 (0.50) | MMP2MMP3MMP1MMP9MMP7 | |
| SCHEMBL4618893 | 0.88 | MMP2 (0.48) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL4887647 | 0.88 | MMP2 (0.48) | MMP2MMP3MMP1EPHX2TSHR | |
| SCHEMBL14066497 | 0.85 | TSHR (0.44) | EPHX2TSHRSLC6A5PHGDH | |
| SCHEMBL4884035 | 0.83 | MMP2 (0.56) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL4884939 | 0.81 | MMP3 (0.52) | MMP2MMP3MMP1MMP9MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | PDF, PEPD, DHPS | MMP2 315/4885MMP3 362/4885MMP1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.